Panel Discussion with Pharma
Get the latest updates on clinical trials for Angelman Syndrome from the 2021 FAST Science Summit. Learn about trial progress, patient selection, drug access, and future plans from leading pharma representatives.
Overview of the Therapeutic Landscape for Angelman Syndrome
Explore the therapeutic landscape for Angelman Syndrome with Allyson Berent, Chief Science Officer at FAST. Discover potential treatments, genetic insights, and the importance of research collaboration.
Now Is the Time for Molecular Therapies for Angelman Syndrome
Explore the potential of molecular therapies for Angelman Syndrome. Learn about gene therapy, viral-based therapies, and antisense oligonucleotides, and how they can address this genetic disorder.
NNZ-2591 as a Potential Treatment for Angelman Syndrome
Explore Neuron Pharmaceuticals’ NNZ-2591, a promising treatment for Angelman syndrome. Learn about its development stages, how it works, and its potential benefits in addressing this rare neurodevelopmental disorder.
Ionis Pharmaceuticals Angelman Syndrome Program Update
Explore Ionis Pharmaceuticals’ progress in their Angelman Syndrome program, including a clinical trial initiation, collaborations for research, and an introduction to the Halos trial. Stay updated with the latest developments.
Hematopoietic Stem Cell Gene Therapy for Angelman Syndrome: Progress and Process
Explore the progress of hematopoietic stem cell gene therapy for Angelman syndrome. Learn about the process, preclinical studies, future clinical trials, and the potential benefits of this promising treatment.
Genetic Approaches for Treating Angelman Syndrome
Explore the latest genetic approaches to treat Angelman Syndrome, including gene therapy, genome editing, and RNA interference. Learn about the challenges, clinical trials, and future directions.
Gene Therapy for Angelman Syndrome through RNA Interference
Explore the potential of RNA gene therapy for Angelman syndrome. This one-time injection could last a lifetime, potentially increasing UBE3A expression and alleviating symptoms.
GTX-102 Phase 1/2 Clinical Trial Update, Development of an ASO for Angelman Syndrome: Science and Regulation
Get the latest on the GTX-102 Phase 1/2 clinical trial for Angelman syndrome treatment. Discover trial protocol, safety concerns, preliminary results, and future directions.
Engineering Human Stem Cell Models for Multiple Angelman Syndrome (Epi)Genotypes
Explore the groundbreaking research at North Carolina State University on engineering human stem cell models for multiple Angelman Syndrome genotypes and epigenotypes. Discover our unique approach and dedication to understanding and addressing this complex condition.